OPKO Health Q1 Loss Improves to $54.8M; Diagnostics Breakeven by Mid-Year
OPKO Health’s Q1 net loss narrowed to $54.8 million from $67.6 million, with a pharmaceutical operating loss of $30 million despite BARDA contract delays reducing revenue. Diagnostics is on track for mid-year breakeven, the Regeneron deal holds over $1 billion in milestones, and five MODEX programs are in clinical trials.
1. Financial Performance
OPKO Health reported a Q1 net loss of $54.8 million, an improvement from $67.6 million a year earlier. The pharmaceutical segment's operating loss narrowed to $30 million, though revenue fell below guidance due to delays under the BARDA contract.
2. Diagnostics Business
Restructuring efforts have positioned the diagnostics unit to reach breakeven by mid-year. Management expects double-digit growth in 4K score test volumes to support revenue recovery in the second half.
3. Regeneron Collaboration
The collaboration with Regeneron has advanced to trigger over $1 billion in milestone payments, with additional future royalty potential based on sales achievements.
4. MODEX Pipeline Progress
OPKO accelerated its MODEX development, moving five programs into clinical trials across vaccines, oncology and immunology, demonstrating broader pipeline diversification.